HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

M Talamonti Selected Research

dalbavancin

2/2018Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


M Talamonti Research Topics

Disease

24Psoriasis (Pustulosis Palmaris et Plantaris)
12/2020 - 04/2007
4Atopic Dermatitis (Atopic Eczema)
04/2021 - 01/2019
2COVID-19
01/2021 - 12/2020
2Obesity
11/2019 - 07/2016
2Respiratory Tract Infections (Respiratory Tract Infection)
06/2017 - 12/2016
2Nasopharyngitis
06/2017 - 12/2016
2Arthralgia (Joint Pain)
06/2017 - 12/2016
2Headache (Headaches)
06/2017 - 12/2016
1Eczema
01/2020
1Exanthema (Rash)
01/2020
1Non-alcoholic Fatty Liver Disease
11/2019
1Dermatitis
01/2019
1Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
07/2018
1Candidiasis (Moniliasis)
07/2018
1Infections
02/2018
1Bacterial Infections (Bacterial Infection)
02/2018
1Metabolic Syndrome (Dysmetabolic Syndrome X)
07/2016
1Genetic Predisposition to Disease (Genetic Predisposition)
08/2013
1Psoriatic Arthritis
01/2012
1Progressive Multifocal Leukoencephalopathy
01/2011
1Necrosis
01/2009
1Heart Failure
04/2007
1Skin Diseases (Skin Disease)
04/2007
1Carcinoma (Carcinomatosis)
05/2001
1Neoplasms (Cancer)
05/2001

Drug/Important Bio-Agent (IBA)

7Ustekinumab (CNTO 1275)FDA Link
01/2020 - 01/2010
6Interleukin-17 (Interleukin 17)IBA
01/2020 - 06/2017
5Biological ProductsIBA
01/2020 - 04/2007
4secukinumabIBA
01/2020 - 09/2018
4Adalimumab (Humira)FDA Link
10/2018 - 01/2009
4Pharmaceutical PreparationsIBA
02/2018 - 01/2011
3ixekizumabIBA
01/2020 - 01/2019
3Proteins (Proteins, Gene)FDA Link
01/2020 - 05/2001
3brodalumabIBA
01/2019 - 12/2016
3efalizumab (Raptiva)FDA Link
01/2011 - 04/2007
3Etanercept (Enbrel)FDA Link
04/2010 - 01/2009
2dupilumabIBA
04/2021 - 08/2020
2Monoclonal AntibodiesIBA
11/2019 - 04/2007
2Interleukin-23 (Interleukin 23)IBA
11/2019 - 07/2018
2InterleukinsIBA
11/2019 - 07/2018
2Interleukin-12 (IL 12)IBA
11/2019 - 08/2013
2CytokinesIBA
11/2019 - 07/2018
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
11/2019 - 10/2018
2HLA-C Antigens (HLA-C)IBA
08/2017 - 01/2016
2Infliximab (Remicade)FDA Link
01/2010 - 01/2009
1Untranslated Regions (Untranslated Region)IBA
01/2020
1Interleukin-17 ReceptorsIBA
11/2019
1Interleukin-23 Subunit p19IBA
07/2018
1guselkumabIBA
07/2018
1Interleukin-22 (IL-22)IBA
07/2018
1dalbavancinIBA
02/2018
1Biomarkers (Surrogate Marker)IBA
07/2016
1Adenosine Triphosphate (ATP)IBA
07/2016
1tofacitinibIBA
07/2016
1Oligonucleotide ProbesIBA
01/2016
1HLA-C*06 antigenIBA
08/2013
1ametantrone (HAQ)IBA
01/2012
1C-Reactive ProteinIBA
01/2012
1amsonic acid (DAS)IBA
01/2012
1SuspensionsIBA
01/2011
1Tumor Necrosis Factor InhibitorsIBA
01/2009
1Alefacept (Amevive)FDA Link
01/2009
1Thymidylate SynthaseIBA
05/2001

Therapy/Procedure

7Biological Therapy
12/2020 - 04/2007
6Therapeutics
04/2021 - 04/2007
1Ambulatory Care (Outpatient Care)
02/2018
1Complementary Therapies (Alternative Medicine)
01/2011
1Drug Therapy (Chemotherapy)
05/2001